GlassScriptPhysician profile
Sallie J Walker
NPI 1306889878
$5,440.82
in general payments reported to CMS, 2019-2025
46 companies · $679 in 2025
The $679 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $434 · 2022: $1,520 · 2023: $1,612 · 2024: $1,195 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,360 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,360.23 |
| Education | $126.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $476.75 | 2021-2025 | Enhertu, Lynparza |
| Seagen INC. | $452.52 | 2021-2023 | Padcev, Tukysa |
| Janssen Biotech, INC. | $385.41 | 2021-2025 | Erleada, Carvykti, Tecvayli |
| Pfizer INC. | $310.58 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $310.51 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $304.58 | 2021-2025 | |
| Incyte Corporation | $276.11 | 2022-2025 | Jakafi, Zynyz, Monjuvi |
| Daiichi Sankyo INC. | $250.98 | 2022-2025 | Enhertu, Datroway |
| Genentech USA, INC. | $216.94 | 2021-2025 | Tecentriq, Phesgo, Itovebi |
| Eisai INC. | $190.34 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $172.52 | 2021-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Genzyme Corporation | $164.64 | 2021-2025 | |
| Astellas Pharma US INC | $157.69 | 2021-2025 | Padcev, Xospata, Xtandi |
| Lilly USA, LLC | $154.96 | 2021-2025 | Verzenio, Retevmo, Jaypirca |
| Regeneron Healthcare Solutions, INC. | $135.94 | 2022-2024 | Libtayo |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $125.33 | 2022-2025 | |
| Abbvie INC. | $107.50 | 2021-2023 | |
| Amgen INC. | $100.85 | 2021-2023 | Blincyto, Kyprolis, Lumakras |
| Celgene Corporation | $97.22 | 2021-2025 | Reblozyl, Opdualag |
| Tersera Therapeutics LLC | $79.90 | 2023-2024 | Zoladex |
| E.R. Squibb & Sons, L.L.C. | $74.88 | 2022-2024 | Opdivo |
| Gilead Sciences, INC. | $66.10 | 2022-2025 | Trodelvy |
| Exelixis INC. | $60.03 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $58.25 | 2022-2023 | Ultomiris |
| Cti Biopharma Corp. | $57.04 | 2022-2023 | Vonjo |
| Pharmacyclics LLC, An Abbvie Company | $54.71 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $54.39 | 2022-2023 | Rezlidhia, Tavalisse |
| Stemline Therapeutics INC. | $53.86 | 2024 | Orserdu |
| Shield Therapeutics INC | $47.19 | 2025 | |
| Array Biopharma INC | $46.91 | 2022-2024 | Braftovi, Lorbrena, Mektovi |
| Myriad Genetic Laboratories, INC. | $42.06 | 2021-2024 | Precisetumor |
| Ge Healthcare | $40.45 | 2022 | |
| Mirati Therapeutics, INC. | $36.24 | 2023-2024 | Krazati |
| Aveo Pharmaceuticals, INC. | $35.83 | 2022-2023 | Fotivda |
| Puma Biotechnology, INC. | $32.88 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $32.14 | 2022 | |
| Sun Pharmaceutical Industries INC. | $24.03 | 2022 | |
| Taiho Oncology, INC. | $20.49 | 2022 | |
| Geron Corporation | $18.84 | 2025 | Rytelo |
| Tempus Ai, INC | $18.76 | 2025 | Xt Cdx |
| Kyowa Kirin, INC. | $17.68 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $17.48 | 2022 | |
| Myovant Sciences INC. | $16.13 | 2022 | |
| Springworks Therapeutics, INC. | $16.00 | 2025 | Ogsiveo |
| Menarini Silicon Biosystems, INC. | $15.21 | 2024 | |
| Dova Pharmaceuticals | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sallie Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.